Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | WRN | Q14191 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681192 | 0.86 | NAAA (0.52) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| Methane SCHEMBL6300031 | 0.83 | NAAA (0.50) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL10249594 | 0.83 | — | — | |
| SCHEMBL26669061 | 0.82 | NAAA (0.52) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL5210881 | 0.80 | ALDH1A1 (0.50) | ALDH1A1CYP1A2TSHRLMNAFFAR3 | |
| SCHEMBL9129791 | 0.78 | ALDH1A1 (0.50) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| Propionic Acid SCHEMBL15282786 | 0.78 | FFAR3 (0.59) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL1276385 | 0.78 | ADRA2A (0.39) | ALDH1A1CYP1A2BLMTSHRLMNA | |
| SCHEMBL9129481 | 0.77 | DGKA (0.52) | ALDH1A1CYP1A2TSHRLMNATDP1 | |
| SCHEMBL2979208 | 0.76 | ALDH1A1 (0.52) | NAAAALDH1A1CYP1A2HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5401868-A | Sulfiding and esterification to form chemical intermediates | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUCTIONSAKTIESELSKAB) (DK) | 1995-03-28 | — | — | US | claimed |
| EP-0541550-B1 | NEW INTERMEDIATES, THEIR PRODUCTION AND USE | LEO PHARM PROD LTD (DK) | 1994-09-07 | — | — | EP | claimed |
| US-8524691-B2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524691-B2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010019511-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-7265140-B2 | Acyloxymethylcarbamate prodrugs of oxazolidinones | PFIZER INC (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1668005-B1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1668005-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | Pharmacia & Upjohn Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | PHARMACIA & UPJOHN COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1373247-A2 | SPIROISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002079189-A2 | SPIROISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION AND INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2002-10-10 | — | — | WO | disclosed |
| US-6376548-B1 | FUNGICIDES; HERBICIDES; INSECTICIDES | ROHM AND HAAS COMPANY | 2002-04-23 | — | — | US | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| US-5401868-A | Sulfiding and esterification to form chemical intermediates | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUCTIONSAKTIESELSKAB) (DK) | 1995-03-28 | — | — | US | disclosed |
| EP-0541550-B1 | NEW INTERMEDIATES, THEIR PRODUCTION AND USE | LEO PHARM PROD LTD (DK) | 1994-09-07 | — | — | EP | disclosed |
| EP-0541550-A1 | NEW INTERMEDIATES, THEIR PRODUCTION AND USE. | LEO PHARM PROD LTD (DK) | 1993-05-19 | — | — | EP | disclosed |
| WO-1991010639-A1 | NEW INTERMEDIATES, THEIR PRODUCTION AND USE | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | NAAA 794/4885ALDH1A1 3493/4885CYP1A2 3865/4885 |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | HDAC3, HDAC1, OGA | NAAA 82/4885ALDH1A1 591/4885CYP1A2 1028/4885 |
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | KCNN1, KCNN2, KCNN3 | NAAA 3627/4885ALDH1A1 1229/4885CYP1A2 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.